id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-284655-zemns7wd	Calvo-Pinilla, Eva	Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge	2015-01-30		.txt	text/plain	4737	225	51	Previous studies show that a recombinant modified vaccinia Ankara (MVA) virus expressing VP2 of AHSV serotype 4 (MVA-VP2) induced virus neutralising antibodies in horses and protected interferon alpha receptor gene knock-out mice (IFNAR −/−) against challenge. Follow up experiments indicated that passive transfer of antiserum, from MVA-VP2 immune donors to recipient mice 1 h before challenge, conferred complete clinical protection and significantly reduced viraemia. In this paper, follow-up studies investigating the relative contribution of humoral and cell-mediated immunity to the protection conferred by MVA-VP2 vaccination, using passive immunisation of naïve recipient IFNAR À/À mice with splenocytes or antiserum from MVA-VP2 vaccinated mice, are described. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation	./cache/cord-284655-zemns7wd.txt	./txt/cord-284655-zemns7wd.txt